Ana Sayfa › Miyelodisplastik Sendromlar › Texas › Houston
Houston, TX içinde Miyelodisplastik Sendromlar klinik çalışmaları
Miyelodisplastik Sendromlar için 43 çalışma, Houston ve çevresindeki (yaklaşık 30 mil mesafedeki) merkezlerde katılımcı arıyor. Kimlerin katılabileceğini ve çalışma ekibine nasıl ulaşılacağını görmek için bir çalışmayı açın.
Resmi çalışma metni (İngilizce)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Katılımcı aranıyorEvre 1
- University of Texas MD Anderson Cancer Center, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Katılımcı aranıyorEvre 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Katılımcı aranıyorEvre 1/2
- MD Anderson Cancer Center, Houston
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 1/2
- M D Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Katılımcı aranıyorEvre 1/2
- MD Anderson, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Katılımcı aranıyorEvre 3
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Katılımcı aranıyorEvre 1
- M D Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Katılımcı aranıyorEvre 1/2
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
Katılımcı aranıyorEvre 1/2
- Md Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Katılımcı aranıyorEvre 2Sağlıklı gönüllüler kabul ediliyor
- MD Anderson Cancer Center, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Katılımcı aranıyorEvre 1
- The University of Texas MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 1/2
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Katılımcı aranıyorEvre 3
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Katılımcı aranıyorEvre 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Katılımcı aranıyorEvre 3
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Katılımcı aranıyorEvre 2
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Katılımcı aranıyorEvre 2/3Sağlıklı gönüllüler kabul ediliyor
- M D Anderson Cancer Center, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Katılımcı aranıyorEvre 1/2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Katılımcı aranıyorEvre 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Katılımcı aranıyorEvre 1/2
- Research Site, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Katılımcı aranıyorEvre 2
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Katılımcı aranıyorEvre 1
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Katılımcı aranıyorEvre 1
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 2
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Katılımcı aranıyorEvre 1
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Katılımcı aranıyorEvre 1
- MD Anderson, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Katılımcı aranıyorEvre 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Katılımcı aranıyorEvre 2/3
- MD Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Katılımcı aranıyorEvre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Katılımcı aranıyorEvre 1
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Katılımcı aranıyorEvre 1/2
- MDACC, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Katılımcı aranıyorEvre 1
- MD Anderson, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Katılımcı aranıyorEvre 1Sağlıklı gönüllüler kabul ediliyor
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Katılımcı aranıyorGözlemsel çalışma
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
Katılımcı aranıyorEvre 1
- MD Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Katılımcı aranıyorEvre 1
- The University of Texas MD Anderson Cancer Center, Houston
Diğer şehirlerde Miyelodisplastik Sendromlar çalışmaları
- Baldwin Park, CA26 çalışma
- New York City, NY21 çalışma
- Seattle, WA21 çalışma
- Washington, DC20 çalışma
- Boston, MA19 çalışma
- Tampa, FL19 çalışma
- Miami, FL17 çalışma
- Columbus, OH14 çalışma
- Durham, NC14 çalışma
- Chicago, IL13 çalışma
- Atlanta, GA13 çalışma
- St. Louis, MO13 çalışma
Houston içinde diğer çalışmalar
- Küçük Hücreli Olmayan Akciğer Kanseri145 çalışma
- Meme Kanseri126 çalışma
- Kanser (tüm türler)121 çalışma
- Metastatik Kanser104 çalışma
- Kolorektal Kanser102 çalışma
- Yumurtalık Kanseri89 çalışma
- Akut Miyeloid Lösemi85 çalışma
- Akciğer Kanseri78 çalışma
- Prostat Kanseri76 çalışma
- Endometrium Kanseri68 çalışma
- Pankreas Kanseri61 çalışma
- Melanom59 çalışma
ClinicalTrials.gov'dan alınmıştır, veri tarihi: 5 Eki 2026. Her çalışma kendi uygunluk kriterlerini belirler; katılım kararı çalışma ekibine aittir.